Capricor Therapeutics, Inc. (CAPR) stock
CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.53−0.71 (-6.93%)
Close on Nov 13, 2026Market cap $554.07MP/E –Yield –
Capricor Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Capricor Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $108.93M, up 43.6% year over year. For fiscal 2025 it was $84.45M, up 69.0% from the year before. Over ten years it grew 19.9% a year on average. The highest annual figure on record is $84.45M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.45M | +69.0% |
| FY2024 | Dec 31, 2024 | $49.97M | +37.1% |
| FY2023 | Dec 31, 2023 | $36.45M | +67.1% |
| FY2022 | Dec 31, 2022 | $21.82M | +60.8% |
| FY2021 | Dec 31, 2021 | $13.57M | +60.5% |
| FY2020 | Dec 31, 2020 | $8.46M | +64.5% |
| FY2019 | Dec 31, 2019 | $5.14M | -57.4% |
| FY2018 | Dec 31, 2018 | $12.07M | +12.1% |
| FY2017 | Dec 31, 2017 | $10.77M | -32.9% |
| FY2016 | Dec 31, 2016 | $16.04M | +16.6% |
| FY2015 | Dec 31, 2015 | $13.76M | +76.7% |
| FY2014 | Dec 31, 2014 | $7.79M | +49.8% |
| FY2013 | Dec 31, 2013 | $5.20M | +97.3% |
| FY2012 | Dec 31, 2012 | $2.63M | -36.3% |
| FY2011 | Dec 31, 2011 | $4.14M | +1.4% |
| FY2010 | Dec 31, 2010 | $4.08M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $29.56M | +45.2% |
| Q2 FY2026 | Jun 30, 2026 | $28.87M | +30.9% |
| Q1 FY2026 | Mar 31, 2026 | $27.38M | +44.7% |
| Q4 FY2025 | Dec 31, 2025 | $23.13M | +58.9% |
| Q3 FY2025 | Sep 30, 2025 | $20.36M | +72.4% |
| Q2 FY2025 | Jun 30, 2025 | $22.05M | +76.3% |
| Q1 FY2025 | Mar 31, 2025 | $18.92M | +70.4% |
| Q4 FY2024 | Dec 31, 2024 | $14.55M | +46.4% |
| Q3 FY2024 | Sep 30, 2024 | $11.81M | +17.7% |
| Q2 FY2024 | Jun 30, 2024 | $12.50M | +41.8% |
| Q1 FY2024 | Mar 31, 2024 | $11.10M | +44.9% |
| Q4 FY2023 | Dec 31, 2023 | $9.94M | +59.5% |
| Q3 FY2023 | Sep 30, 2023 | $10.03M | +82.2% |
| Q2 FY2023 | Jun 30, 2023 | $8.82M | +77.6% |
| Q1 FY2023 | Mar 31, 2023 | $7.66M | +49.8% |
| Q4 FY2022 | Dec 31, 2022 | $6.23M | +46.2% |
| Q3 FY2022 | Sep 30, 2022 | $5.50M | +119.0% |
| Q2 FY2022 | Jun 30, 2022 | $4.97M | +42.0% |
| Q1 FY2022 | Mar 31, 2022 | $5.12M | +55.2% |
| Q4 FY2021 | Dec 31, 2021 | $4.26M | +55.3% |
| Q3 FY2021 | Sep 30, 2021 | $2.51M | -4.4% |
| Q2 FY2021 | Jun 30, 2021 | $3.50M | +81.4% |
| Q1 FY2021 | Mar 31, 2021 | $3.30M | +185.4% |
| Q4 FY2020 | Dec 31, 2020 | $2.75M | +231.2% |
| Q3 FY2020 | Sep 30, 2020 | $2.63M | +206.5% |
| Q2 FY2020 | Jun 30, 2020 | $1.93M | +17.2% |
| Q1 FY2020 | Mar 31, 2020 | $1.16M | -36.2% |
| Q4 FY2019 | Dec 31, 2019 | $828.75K | -70.9% |
| Q3 FY2019 | Sep 30, 2019 | $857.76K | -72.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.64M | -51.5% |
| Q1 FY2019 | Mar 31, 2019 | $1.81M | -32.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.85M | +13.1% |
| Q3 FY2018 | Sep 30, 2018 | $3.13M | +68.2% |
| Q2 FY2018 | Jun 30, 2018 | $3.39M | +8.3% |
| Q1 FY2018 | Mar 31, 2018 | $2.70M | -17.2% |
| Q4 FY2017 | Dec 31, 2017 | $2.52M | -5.5% |
| Q3 FY2017 | Sep 30, 2017 | $1.86M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.13M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.67M | – |
See a number that looks wrong?